NCT02173665已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 主要终点
- Number of patients with clinically significant changes in vital signs (blood pressure [BP], heart rate [HR])
研究概览
简要总结
The objective of the current study was to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1356 BS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 65 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (Blood pressure (BP), Heart Rate (HR), 12-lead Electrocardiogram (ECG)), clinical laboratory tests
- •Age ≥21 and Age ≤65 years
- •BMI ≥18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index)
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to the drug or its excipients and lactose intolerance)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of study centre
- •Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval > 110 ms or QTcB > 450 ms or QT >500 ms
研究组 & 干预措施
BI 1356 BS - Powder in bottle (PIB)
Experimental
干预措施: BI 1356 BS - Powder in bottle (PIB) (Drug)
BI 1356 BS - Tablet
Experimental
干预措施: BI 1356 BS - Tablet (Drug)
Placebo
Active Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with clinically significant changes in vital signs (blood pressure [BP], heart rate [HR])
时间窗: Screening, up to 16 days after drug administration
Number of patients with abnormal changes in laboratory parameters
时间窗: Screening, up to 16 days after drug administration
Assessment of tolerability by investigator on a 4-point scale
时间窗: up to 16 days after drug administration
Number of patients with adverse events
时间窗: up to 30 days
Number of patients with abnormal findings in physical examination
时间窗: Screening, up to 16 days after drug administration
Number of patients with clinically significant changes in 12-lead electrocardiogram (ECG)
时间窗: Screening, up to 16 days after drug administration
次要结局
- AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)(predose, up to 192 h following drug administration)
- t1/2 (terminal half-life of the analyte in plasma)(predose, up to 192 h following drug administration)
- tmax (time from dosing to maximum concentration)(predose, up to 192 h following drug administration)
- %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)(predose, up to 192 h following drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(predose, up to 192 h following drug administration)
- Cmax (maximum concentration of the analyte in plasma)(predose, up to 192 h following drug administration)
- AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(predose, up to 192 h following drug administration)
- MRTpo (mean residence time of the analyte in the body after po administration)(predose, up to 192 h following drug administration)
- CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)(up to 120 h following drug administration)
- λz (terminal rate constant in plasma)(predose, up to 192 h following drug administration)
- CL/F (total clearance of the analyte in the plasma after extravascular administration)(predose, up to 192 h following drug administration)
- fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)(up to 120 h following drug administration)
- Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2)(up to 120 h following drug administration)
- Changes of Dipeptidyl-Peptidase IV (DPP-IV) activity in plasma(predose, up to 96 h following drug administration)
研究者
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01282970Boehringer Ingelheim72
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy AdultsHealthyNCT01050127Abbott36
已完成
1 期
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly SubjectsHealthyNCT00968422Abbott28
已完成
1 期
Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.HealthyNCT01291732Boehringer Ingelheim48
Unknown
1 期
Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy PatientsNeutropeniaNCT01637493Hangzhou Jiuyuan Gene Engineering Co. Ltd.,24